University of Arizona College of Medicine-Phoenix.
University of Arizona College of Medicine-Phoenix; University of Arizona Sarver Heart Center, Tucson.
Am J Med. 2023 Oct;136(10):994-999. doi: 10.1016/j.amjmed.2023.06.004. Epub 2023 Jun 24.
Percutaneous coronary intervention (PCI) in patients with chronic total occlusion is commonly performed despite unclear long-term benefits. The goal of this study was to evaluate the postprocedural outcome of patients with chronic total occlusion intervention.
The National Inpatient Sample database, years 2016-2020, was studied using International Classification of Diseases, Tenth Revision codes. Patients with chronic total occlusion interventions were compared with patients without chronic total occlusion. We evaluated postprocedural mortality and complications.
PCI in patients with chronic total occlusion was associated with higher total inhospital mortality and all postprocedural complications. A weighted total of 10,059,269 patients underwent PCI, with 259,574 having chronic total occlusion. The chronic total occlusion group had a 3.17% mortality rate vs 2.57% of nonchronic total occlusion PCIs (odds ratio [OR] 1.24; 95% confidence interval [CI], 1.18-1.31; P < .001). Using multivariate analysis adjusting for basline charcteristics and high risk features such as age, sex, race, diabetes mellitus, chronic kidney disease, systolic heart failure, 3-vessel PCI, hypertension, chronic obstructive pulmonary disease, ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, prior PCI, history of coronary artery bypass graft, history of anemia, smoking status, atrial fibrillation/flutter, valvular heart disease, and , history of stroke, chronic total occlusion PCI remained significantly associated with higher total mortality (OR 1.07; 95% CI, 1.02-1.13; P = .02). Patients with chronic total occlusion compared with nonchronic total occlusion PCI had also higher rates of myocardial infarction (OR 2.85; 95% CI, 2.54-3.21; P < .001), coronary perforation (OR 6.01; 95% CI, 5.25-6.89; P < .001), tamponade (OR 3.36; 95% CI, 2.91-3.88; P < .001), contrast-induced nephropathy (OR 2.05; 95% CI, 1.45-2.90; P < .001), procedural bleeding (OR 3.57; 95% CI, 3.27-3.89; P < .001), and acute postprocedural respiratory failure (OR 2.07; 95% CI, 1.81-2.36; P < .001). All postprocedural complications were more than 3 times the nonchronic total occlusion patients (OR 3.45; 95% CI, 3.24-3.67; P < .001).
Using a large national inpatient database, PCI performed in patients with chronic total occlusion was associated with significantly much higher mortality and postprocedural complications compared with PCI in nonchronic total occlusion patients.
尽管慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)的长期获益并不明确,但该治疗方法仍在广泛应用。本研究旨在评估 CTO 介入治疗患者的术后结局。
利用 2016-2020 年美国国家住院患者样本数据库,采用国际疾病分类第十次修订版编码进行研究。将 CTO 介入治疗患者与无 CTO 介入治疗患者进行比较。我们评估了术后死亡率和并发症。
与非 CTO 组相比,CTO 组患者接受 PCI 治疗后院内总死亡率和所有术后并发症的发生率均更高。共有 10059269 例患者接受了 PCI,其中 259574 例为 CTO。CTO 组的死亡率为 3.17%,而非 CTO 组为 2.57%(比值比 [OR] 1.24;95%置信区间 [CI],1.18-1.31;P <.001)。通过调整基线特征和高危特征(如年龄、性别、种族、糖尿病、慢性肾脏病、收缩性心力衰竭、3 支血管 PCI、高血压、慢性阻塞性肺疾病、ST 段抬高型心肌梗死、非 ST 段抬高型心肌梗死、既往 PCI、冠状动脉旁路移植术史、贫血史、吸烟状况、心房颤动/扑动、心脏瓣膜病和中风史)后的多变量分析显示,CTO 组的死亡率仍显著高于非 CTO 组(OR 1.07;95% CI,1.02-1.13;P =.02)。与非 CTO 组相比,CTO 组患者的心肌梗死(OR 2.85;95% CI,2.54-3.21;P <.001)、冠状动脉穿孔(OR 6.01;95% CI,5.25-6.89;P <.001)、心脏压塞(OR 3.36;95% CI,2.91-3.88;P <.001)、对比剂肾病(OR 2.05;95% CI,1.45-2.90;P <.001)、手术出血(OR 3.57;95% CI,3.27-3.89;P <.001)和急性术后呼吸衰竭(OR 2.07;95% CI,1.81-2.36;P <.001)的发生率也更高。所有术后并发症的发生率均高于非 CTO 组(OR 3.45;95% CI,3.24-3.67;P <.001)。
利用大型全国住院患者数据库,与非 CTO 组相比,CTO 患者接受 PCI 治疗后的死亡率和术后并发症发生率明显更高。